Chicago—Extending aromatase inhibitor (AI) therapy beyond five years lowered the risk for recurrence by 34% in postmenopausal women with early-stage breast cancer during the Canadian Cancer Trials Group’s Phase III MA.17R trial. But some experts question the value of extending therapy and stress the need for discussions with individual patients.
The results were reported in two abstracts at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO) (abstracts LBA1